Candel Therapeutics (CADL) FCF Margin (2020 - 2022)
Candel Therapeutics (CADL) posted FCF Margin of 19138.71% for Q4 2022, up 41.55% sequentially from 32745.16% in Q3 2022, and up 4459462.0% YoY from N/an in Q4 2021.
Candel Therapeutics (CADL) FCF Margin (2020 - 2022) Analysis & Trends
Candel Therapeutics has reported FCF Margin for 3 years, with the latest figure at 19138.71% in Q4 2022.
- Quarterly FCF Margin rose 4459462.0% year-over-year to 19138.71% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 25393.55% (down 303496.0% YoY) and the FY2022 annual result came in at 25190.4%, down 305540.0% from the prior year.
- FCF Margin rose to 19138.71% in Q4 2022 per CADL's latest filing, from 32745.16% in the prior quarter.
- Over five years, FCF Margin peaked at 4119.35% in Q3 2020 and troughed at 63733.33% in Q4 2021.
- A 3-year average of 23955.91% and a median of 21843.55% in 2021 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2021 and 2022: FCF Margin tumbled 5266882 bps in 2021, then jumped 4459462 bps in 2022.
- Over 3 years, FCF Margin stood at 11064.52% in 2020, then slumped by 476 bps to 63733.33% in 2021, then soared by 70 bps to 19138.71% in 2022.
- According to Business Quant data, FCF Margin over the past three periods registered 19138.71%, 32745.16%, and 22354.84% for Q4 2022, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -19,138.71% |
| Sep 30, 2022 | -32,745.16% |
| Jun 30, 2022 | -22,354.84% |
| Mar 31, 2022 | -27,335.48% |
| Dec 31, 2021 | -63,733.33% |
| Sep 30, 2021 | -21,332.26% |
| Jun 30, 2021 | -13,616.13% |
| Mar 31, 2021 | -24,119.35% |
| Dec 31, 2020 | -11,064.52% |
| Sep 30, 2020 | -4,119.35% |